Good Start for local businesses
Thursday, 22 July, 2004
Life science companies - from start-ups to listed biotechs - featured highly in the latest round of Commonwealth R&D Start funding, it was revealed yesterday.
About a dozen life science-related firms netted more than AUD$15 million of the total pool of $65.15 million awarded between April 2 and June 30.
Among them were listed company Agen Biomedical, a division of listed company Agenix (ASX:AGX), which was awarded more than $1.128 million towards the continued development of its Thromboview blood clot imaging technology.
The biggest grant overall was one of almost $9.4 million to Seeley International, for its integrated climate control system.
Life science grantees included:
- Vaxine (ACT), $764,996 -- Novel, aluminium-free hepatitis B vaccine
- Biosceptre (NSW), $2,091,077 -- Broad-spectrum anti-cancer topical cream
- Zestwin (NSW), $175,000 --- Non-toxic chemical coating for sheep
- CathRX (NSW) with University of Western Sydney, $1,496,593 -- Sensing and ablation range for abnormal heart rhythms
- Agen Biomedical (Qld), $1.128,758 -- ThromboView
- Glycoz (Qld), $1,838,000 -- New carbohydrate-based antibiotic
- Genetraks (Qld), $1,015,816 -- Gene-based diagnostic test for EPM
- Hexima (Vic), $656,197 -- Insect-resistant technology in cotton
- Ultimate Medical (Vic), $264,783 -- Novel single-use medical airway device
- GBC Scientific Equipment (Vic), $1,837,555 -- New HPLC instrumentation
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
